There is one clinical trial.
This randomized, ascending dose Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
Description: Absence of device-related serious adverse events or any patterns of severity ≥2 device-related adverse eventsMeasure: Primary Safety Measure Time: Baseline thru Day 8
Description: Time weighted average change in viral load from baseline by RT-qPCR from Day 1 to Day 8.Measure: Primary Efficacy Measure Time: Baseline to Day 8
Description: Geometric mean viral load as measured in saliva on day 1, 3, 5, and 8 by RT-qPCRMeasure: Geometric Mean Viral Load Time: Days 1, 3, 5 and 8
Description: Proportion of subjects demonstrating viral load reduction ≥ 95% by RT-qPCR (at each visit)Measure: Viral Load Reduction Time: Days 1, 3, 5 and 8
Description: Time to clearance of viral infection in saliva, defined as a negative test via RT-qPCRMeasure: Time to Clearance of Viral Infection Time: Days 1, 3, 5 and 8
Description: Proportion of subjects demonstrating clearance of viral infection, defined as a negative test via RT-qPCR on Day 8/ET.Measure: Proportion of Subjects Demonstrating Clearance of Viral Infection Time: Days 1, 3, 5 and 8
Description: Median time to alleviation of symptoms as measured by the time when all eight symptoms (cough, sore throat, nasal congestion, headache, chills/sweats, muscle or joint pain, fatigue, and nausea) had been assessed by the subject as none (0) or mild (1).Measure: Median Time to Alleviation of Symptoms Time: Days 1, 3, 5 and 8
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports